As it does every year, the American Diabetes Association (ADA) made updates to its Standards of Care in Diabetes in 2023.1 Included in these updates was a section on “General Device Principles” and recommendations.
One of these key recommendations is that automated insulin delivery (AID) systems should be offered for diabetes management. For those unfamiliar with this technology, an AID system consists of a continuous glucose monitoring (CGM) sensor, an insulin pump, and a predictive algorithm that can automate insulin dosing.
This was a significant validation for Tandem Diabetes Care, which is committed to creating new possibilities for people living with diabetes, their loved ones, and their healthcare providers through a positively different experience. Tandem Diabetes Care proudly makes the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology. It uses CGM* data to predict glucose levels up to 30 minutes in advance and then automates insulin dosing. This AID system helps prevent highs and lows.
Dr. Jordan Pinsker is a renowned endocrinologist and the Vice President and Medical Director for Tandem Diabetes Care. He’s seen firsthand what an impact automated insulin delivery systems can make.
“Recognition that AID systems are now recommended to everyone with type 1 diabetes is a major milestone and shows how effective these systems are,” Dr. Pinsker said.
“We’re honored to have the #1 rated automated insulin delivery system on the market right now to go along with the #1 rated insulin pump,” said Tandem President and CEO John Sheridan.
Control-IQ technology was recently featured in the New England Journal of Medicine as showing an approximate 3-hour per day increase in time in range in children ages 2-5.3 Read more about the study results.
The ADA’s Standards of Care in Diabetes is a living document that is regularly updated as innovations and new ways to help manage diabetes emerge. It was formerly known as “Standards of Medical Care in Diabetes” and was first approved in 1988.
These are two of the 30 recommendations:
- People with diabetes who have been using continuous glucose monitoring, continuous subcutaneous insulin infusion, and/or automated insulin delivery for diabetes management should have continued access across third-party payers, regardless of age or A1C levels.1
- The Automated insulin delivery systems should be offered for diabetes management to youth and adults with type 1 diabetes and other types of insulin-deficient diabetes who are capable of using the device safely (either by themselves or with a caregiver). The choice of device should be made based on the individual’s circumstances, preferences, and needs.1
* CGM sold separately.
1. ElSayed NA, Aleppo G, Aroda VR, et al. Diabetes Technology: Standards of Care in Diabetes - 2023. Diabetes Care. 2023;46(Suppl. 1):S111-S127. doi: 10.2337/dc23-SINT
2. dQ&A US Patient Panel Q2 2023 (Apr-Jun 2023).
3. Wadwa RP, Reed ZW, Buckingham BA, et al. Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. N Engl J Med. 2023;388:991-1001. DOI: 10.1056/NEJMoa2210834